Coronary heart disease: the percentage of patients with coronary heart disease whose last measured total cholesterol (measured in last 15 months) is 5 mmol/l or less.

Brief Summary

TITLE

SOURCE(S)

British Medical Association (BMA). Quality and outcomes framework guidance for GMS contract 2008/09. London (UK): British Medical Association, National Health Service Confederation; 2008 Apr. 148 p.

Measure Domain

PRIMARY MEASURE DOMAIN

Outcome

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the Measure Validity page.

SECONDARY MEASURE DOMAIN

Does not apply to this measure

Brief Abstract

DESCRIPTION

This measure is used to assess the percentage of patients with coronary heart disease whose last measured total cholesterol (measured in the previous 15 months) is 5 mmol/l or less.

RATIONALE

Coronary heart disease (CHD) is the single commonest cause of premature death in the United Kingdom (UK). The research evidence relating to the management of CHD is well established and if implemented can reduce the risk of death from CHD and improve the quality of life for patients. This measure is one of ten Secondary Prevention of Coronary Heart Disease (CHD) measures. The "Secondary Prevention of Coronary Heart Disease (CHD)" indicator set focuses on the management of patients with established CHD consistent with clinical priorities in the four nations.

A number of Randomised Controlled Trials of statin therapy in the secondary prevention of CHD have shown a reduction in relative risk of cardiac events irrespective of the starting level of cholesterol. Recent trials have found greater relative benefit with more potent cholesterol lowering regimes. It is likely that National Guidelines relating to statin therapy in patients with CHD will change to recommend statin therapy for all patients with CHD irrespective of their starting level of total cholesterol.

However, currently the Joint British Recommendations on Prevention of Coronary Heart Disease in Clinical Practice (1998) and the Scottish Intercollegiate Guidelines Network (SIGN) Guidelines 93, 96 and 97 recommend that patients who have a cholesterol of greater than 5 mmol/l should be offered lipid lowering therapy. This should be treated as an audit target below which to aim for all eligible CHD patients.

The guidance here is given in terms of total cholesterol, as this is used in national guidance and in trials.

PRIMARY CLINICAL COMPONENT

Coronary heart disease; total cholesterol

DENOMINATOR DESCRIPTION

Patients with coronary heart disease

NUMERATOR DESCRIPTION

Number of patients from the denominator whose last measured total cholesterol (measured in the previous 15 months) is 5mmol/l or less

DATA SOURCE

Medical record
Registry data

Identifying Information

ORIGINAL TITLE

CHD 8. The percentage of patients with coronary heart disease whose last measured total cholesterol (measured in the previous 15 months) is 5 mmol/l or less.

MEASURE COLLECTION

Quality and Outcomes Framework Indicators

MEASURE SET NAME

Secondary Prevention of Coronary Heart Disease (CHD)

DEVELOPER

British Medical Association
National Health System (NHS) Confederation

FUNDING SOURCE(S)

The expert panel who developed the indicators are entirely funded by a grant from the English Department of Health.

COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE

The main indicator development group is based in the National Primary Care Research and Development Centre in the University of Manchester. They are: Professor Helen Lester, NPCRDC, MB, BCH, MD; Dr. Stephen Campbell, NPCRDC, PhD; Dr. Umesh Chauhan, NPCRDC, MB, BS, PhD.

Others involved in the development of individual indicators are: Professor Richard Hobbs, Dr. Richard McManus, Professor Jonathan Mant, Dr. Graham Martin, Professor Richard Baker, Dr. Keri Thomas, Professor Tony Kendrick, Professor Brendan Delaney, Professor Simon De Lusignan, Dr. Jonathan Graffy, Dr. Henry Smithson, Professor Sue Wilson, Professor Claire Goodman, Dr. Terry O'Neill, Dr. Philippa Matthews, Dr. Simon Griffin, Professor Eileen Kaner.

FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST

None for the main indicator development group.

ENDORSER

National Health Service (NHS)

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2004 Apr

REVISION DATE

2008 Apr

MEASURE STATUS

Please note: This measure has been updated. The National Quality Measures Clearinghouse is working to update this summary.

SOURCE(S)

British Medical Association (BMA). Quality and outcomes framework guidance for GMS contract 2008/09. London (UK): British Medical Association, National Health Service Confederation; 2008 Apr. 148 p.

MEASURE AVAILABILITY

The individual measure, "CHD 8. The Percentage of Patients with Coronary Heart Disease Whose Last Measured Total Cholesterol (Measured in the Previous 15 Months) is 5 mmol/l or Less," is published in the "Quality and outcomes framework guidance." This document is available from the British Medical Association Web site.

NQMC STATUS

This NQMC summary was completed by ECRI on September 19, 2006. The information was verified by the measure developer on November 1, 2006. This NQMC summary was updated by ECRI Institute on January 7, 2009. The information was verified by the measure developer on February 9, 2009.

COPYRIGHT STATEMENT

No copyright restrictions apply.

Disclaimer

NQMC DISCLAIMER

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

Brief Summary

TITLE

SOURCE(S)

Measure Domain

PRIMARY MEASURE DOMAIN

SECONDARY MEASURE DOMAIN

Brief Abstract

DESCRIPTION

RATIONALE

PRIMARY CLINICAL COMPONENT

DENOMINATOR DESCRIPTION

NUMERATOR DESCRIPTION

DATA SOURCE

Identifying Information

ORIGINAL TITLE

MEASURE COLLECTION

MEASURE SET NAME

DEVELOPER

FUNDING SOURCE(S)

COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE

FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST

ENDORSER

ADAPTATION

RELEASE DATE

REVISION DATE

MEASURE STATUS

SOURCE(S)

MEASURE AVAILABILITY

NQMC STATUS

COPYRIGHT STATEMENT

Disclaimer

NQMC DISCLAIMER

Search

Summary

Browse

Compare